EPW
GILD icon

Evolve Private Wealth’s Gilead Sciences GILD Stock Holding History

Evolve Private Wealth’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55M Sell
20,202
-7,737
-28% -$1.02M 0.16% 124
2026
Q1 		$3.89M Buy
27,939
+2,273
+9% +$318K 0.21% 82
2025
Q4 		$3.15M Buy
+25,666
New +$3.12M 0.19% 100

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evolve Private Wealth's GILD Position: Q2 2026 in Review

Evolve Private Wealth reduced its Gilead Sciences (GILD) stake by 28% in Q2 2026, selling an estimated $1.02M and leaving 20,202 shares worth $2.55M. The position accounts for 0.16% of the portfolio, ranked #124.

Evolve Private Wealth first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.89M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Evolve Private Wealth held 20,202 shares of Gilead Sciences worth $2.55M as of Q2 2026.
  • Evolve Private Wealth sold 7,737 Gilead Sciences shares in Q2 2026, an estimated $1.02M.
  • Gilead Sciences made up 0.16% of Evolve Private Wealth's portfolio in Q2 2026, its #124 holding.
  • Evolve Private Wealth first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Evolve Private Wealth's Gilead Sciences position peaked at $3.89M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.